Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialJeffrey L. Lennox, Peter Sklar, José Valdez Madruga et al.|The Lancet|2009Cited by 620
Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical TrialAndrew Zolopa, Andrew Cheng, Daniel S Berger et al.|The Journal of Infectious Diseases|2010Cited by 114